Enter Note Done
Go to previous page in this tab
Event
  • Scientific Session
  • Bookmark Icon
  • QIVIVE: A NAMs-Powered Framework for Exposure and Risk Assessment
  • Schedule
    Notes
  • Room 304‚ Convention Center
    Set Timezone


Chair: Marjory Moreau, ESQlabs LLC
Co-Chair: Cecilia Tan, US EPA

Primary Endorser: Biological Modeling Specialty Section


Endorser(s): Computational Toxicology Specialty Section


Endorser(s): Women in Toxicology Special Interest Group


As regulatory toxicology increasingly adopts New Approach Methodologies (NAMs), the refinement and application of quantitative in vitro to in vivo extrapolation (QIVIVE) methods have been critical for integrating diverse mechanistic data into defensible risk decisions. This session presents QIVIVE as the support underpinning a Next Generation Risk Assessment (NGRA) paradigm, serving as the structural bridge between in vitro endpoints and human-relevant exposures. Specifically, QIVIVE methods use pharmacokinetic (PK) or physiologically based kinetic (PBK) modeling to provide critical context for in vitro points of departure (PODs) by deriving an external dose (i.e., exposure) that produces plasma or tissue concentrations equivalent to those observed in the assay. Beyond dose translation, an equally critical consideration in QIVIVE is the relationship between in vitro bioactivity and in vivo adversity. Adverse outcome pathways (AOPs) could provide such a biological context. When an assay targets a molecular initiating event (MIE), or a battery perturbs multiple MIEs within an AOP network, QIVIVE becomes more informative for predicting in vivo dose-response that relates to an adverse outcome. Endpoints not anchored to an AOP can still be used for conservative estimation by treating any reproducible in vitro activation as a potential hazard.
Four talks aim to demonstrate QIVIVE's centrality to chemical safety decisions within an NGRA paradigm. The first establishes the foundations of PBK-QIVIVE and their role in translating in vitro points of departure into human-relevant exposures. The second grounds this framework in practice through a military use case, comparing in vitro and in vivo dose-response data for lung, liver, and neurotoxicity endpoints to illustrate how the approach performs against real-world data. The third examines regulatory acceptance through guidance on the documentation and assessment of mechanistic scaffolding (AOPs) and through OECD guidance on PBK validation without in vivo data. The final presentation advances the framework by replacing point-estimate extrapolations with probabilistic, data-standardized approaches that explicitly account for variability, demonstrating that quantifying uncertainty directly increases confidence in using mechanistic data for human health decision-making.
Together, these presentations demonstrate how mechanistic grounding and explicit uncertainty quantification can support meaningful advancements in QIVIVE methodologies, moving beyond solely deterministic calculations to a transparent, defensible regulatory tool that strengthens confidence in NAMs and accelerates the transition to animal-free safety assessment.
Attendees at all levels of familiarity with PBK-QIVIVE will find actionable insights in this session. For those new to these methodologies, the presentations are structured to build intuition progressively: from the core logic of why kinetic modeling is necessary to translate a cell-based concentration into a meaningful human dose, to how uncertainty in that translation can be quantified and communicated to regulators. Practitioners will leave with a clearer understanding of when and how to apply QIVIVE within their own workflows, what biological and mechanistic context is needed to strengthen extrapolations, and what current regulatory guidance exists to support the use of PBK models and AOPs in safety submissions. For more experienced attendees, the session offers concrete examples of the QIVIVE framework, regulatory case studies, and a real-world application that illustrate animal-free risk assessment.
The panel discussion will focus on general acceptance of quantitative in vitro to in vivo extrapolation (QIVIVE) methods as a means to provide the in vivo context needed for human health risk assessment. This necessitates that the communities of practice be able to address critical questions regarding the predictive power, reliability, and applicability of the methods across a wide range of use cases and chemistries. In addition to attendee questions, the speakers and co-chairs will engage in a panel discussion covering topics including: what are the available or anticipated methods for standardizing the diverse in vitro input data required for animal-free pharmacokinetic PBK models; how can the uncertainty characterization provided by probabilistic QIVIVE be used within in a regulatory framework; is the current number of recognized adverse outcome pathways (AOPs) a limiting factor in the development and adoption of new approach methodologies (NAMs) and what types of analyses or advances are possible in the absence of or prior to establishing a wider range of AOPs for environmental (i.e., non-therapeutic).

Session and Activity Type
Presentations